EU

Best Reasonable Efforts to end a global pandemic

Marton Eorsi

Now that the COVID-19 vaccine contract between the EU and AstraZeneca has been published, we take a look at it and the “Best Reasonable Efforts” provisions. The production issues facing the roll-out of the EU vaccination programme have led some to question the centralised approach taken by the European Commission in its procurement of the Read More

EU – Parallel trade in the life sciences sector – Q&A

Francesca Miotto

On Tuesday, 26 January 2021, Allen&Overy (Belgium) LLP hosted a webinar on the key developments in parallel trade of pharmaceuticals in 2020. In this blog post, we discuss a few key topics and questions raised by the webinar’s participants.­ How will the competition law framework apply post-Brexit?­ Post-Brexit, companies active in the UK and the Read More

Parallel trade in the life sciences sector – recent developments

Tine Carmeliet

Please join us on Tuesday, 26 January 2021 for a webinar on the key developments in the parallel trade of pharmaceuticals in 2020.  Tine Carmeliet, Nele De Backer, Francesca Miotto, Geert Glas and Nieke Vanavermaete will talk you through recent decisions and developments in the field of parallel trade, review the impact of both Brexit Read More

European Commission completes current cycle of pay-for-delay probes with fines imposed on Teva and Cephalon

Thomas Masterman

On 26 November 2020, the European Commission (Commission) issued a decision fining pharmaceutical companies Teva and Cephalon EUR60.5 million for infringing Article 101 TFEU by agreeing to delay the entry of a cheaper generic version of Cephalon’s sleep disorder drug modafinil (the Decision). While the Decision completes the current cycle of the Commission’s “pay-for-delay” investigations, Read More

EU Court says off-label treatments must not be considered when assessing the significant benefit criterion in orphan drugs

Tine Carmeliet

On 23 September 2020, the General Court of the European Union (GC) annulled a decision of the European Commission (Commission) that had withdrawn the orphan drug status of Trecondi (Treosulfan). This is an important decision as, for the first time, the GC has disagreed with the Commission’s restrictive approach to finding a “significant benefit” in Read More